Merck KGaA

Merck KGaA secures Chinese approval for Pimicotinib, a dual PDGFR‑β/CSF1R inhibitor showing 53 % ORR in TGCT, boosting oncology access and single‑use bioprocessing growth.

Merck KGaA’s latest market‑intelligence, financial shifts and U.S. Medicaid pricing move show how its reagent supply and drug‑price strategy drive growth and affordability.

Merck KGaA’s solid valuation, diversified oncology and auto‑immune pipeline, and robust response to FDA RSV reviews make it a resilient choice for investors seeking stable pharma growth amid value‑based reimbursement shifts.

Merck KGaA shares rebound after Exane BNP Paribas lifts its target, highlighting Tecentriq pipeline strength, margin gains and new partnership prospects.

Merck KGaA’s modest stock rally follows Exane BNP Paribas’ target hike, yet investors face lingering chemicals‑sector risk, AI‑R&D uncertainty and tightening EU rules—dissecting its fundamentals and hidden upside.

Merck KGaA’s modest share rally shows investors see potential in a new AI partnership to speed drug discovery and boost long‑term growth.

Merck KGaA secures FDA Fast‑Track for cladribine capsules, a potential oral therapy that could improve muscle strength and daily living for patients with generalized myasthenia gravis.

Merck KGaA secures 16 MW of renewable power in South Korea with a 20‑year PPA to hit 80 % renewable electricity by 2030, cutting CO₂ and boosting investor confidence.

Merck KGaA is poised for growth as it advances its antibody-drug conjugate (ADC) therapy into late-stage trials, while also executing a cost-cutting strategy through the closure of its Ireland API facility, positioning the company for long-term succ…

Merck KGaA has entered into two pricing-related agreements with the US government to maintain its market share and avoid tariff exposure, while also positioning itself for future growth through investments in next-generation fertility therapies and …